Long non-coding RNAs : Key regulators in oxaliplatin resistance of colorectal cancer
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies in the world with high relapse and mortality rates. Although oxaliplatin (OXA), a platinum-based anticancer drug, is widely used in CRC treatment, the resulting chemoresistance dramatically attenuates the drug efficacy and increases the failure rate of this therapy. Thus, the study on OXA-induced chemoresistance is extremely urgent. In recent years, emerging evidence has shown that lncRNAs play irreplaceable roles in drug resistance. However, we only have a limited knowledge of the lncRNAs that are closely related to oxaliplatin resistance in CRC. In present study, we identify and characterize these lncRNAs, including their functions, underlying mechanisms and possible applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 128(2020) vom: 24. Aug., Seite 110329 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qi, Fang-Fang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04ZR38536J |
|---|
| Anmerkungen: |
Date Completed 01.03.2021 Date Revised 01.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2020.110329 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310823927 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310823927 | ||
| 003 | DE-627 | ||
| 005 | 20231225140930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2020.110329 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310823927 | ||
| 035 | |a (NLM)32502843 | ||
| 035 | |a (PII)S0753-3322(20)30521-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qi, Fang-Fang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long non-coding RNAs |b Key regulators in oxaliplatin resistance of colorectal cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2021 | ||
| 500 | |a Date Revised 01.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies in the world with high relapse and mortality rates. Although oxaliplatin (OXA), a platinum-based anticancer drug, is widely used in CRC treatment, the resulting chemoresistance dramatically attenuates the drug efficacy and increases the failure rate of this therapy. Thus, the study on OXA-induced chemoresistance is extremely urgent. In recent years, emerging evidence has shown that lncRNAs play irreplaceable roles in drug resistance. However, we only have a limited knowledge of the lncRNAs that are closely related to oxaliplatin resistance in CRC. In present study, we identify and characterize these lncRNAs, including their functions, underlying mechanisms and possible applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chemoresistance | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Long non-coding RNA | |
| 650 | 4 | |a Oxaliplatin | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 700 | 1 | |a Yang, Yunyao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haowen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hongping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 128(2020) vom: 24. Aug., Seite 110329 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2020 |g day:24 |g month:08 |g pages:110329 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2020.110329 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2020 |b 24 |c 08 |h 110329 | ||